In the Ai14/Cre reporter experiment, the plotted fractions were approximately 67% versus 40% tdTomato-positive dendritic cells and approximately 60% versus 40% tdTomato-positive macrophages for AMG514 versus cKK-E12.
Cre mRNA, IV, n=4-5; the figure caption reports 5 micrograms and 48 h, while Methods report 0.25 mg/kg and 72 h · Extended Data Figure 4e and Methodssales@dcchemicals.com
AMG514
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| AMG514 | 35 | Ionizable lipid |
| DOPE | 16 | Helper phospholipid |
| Cholesterol | 46.5 | Sterol |
| DMG-PEG2k | 2.5 | PEG lipid |
| Reported total | 100 | Source values retained |
Component molecular weights and calculated amounts
Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| AMG514 | 35.000 | 51.5894 | 46.7137 | ||
| DOPE | 16.000 | 23.5837 | 17.5470 | ||
| Cholesterol | 46.500 | 68.5402 | 26.5011 | ||
| DMG-PEG2k | 2.500 | 3.6850 | 9.2382 |
Calculated total: 100.0000 mg lipid.
Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.
Literature-reported performance for the cited formulation
Literature-reported97%Post-formulation characterization · Representative cKK-E12 LNP: 56%Supplementary Table 2, internal p. 25 / PDF p. 26
Literature-reported102.7 nmPost-formulation characterization · Representative cKK-E12 LNP: 86.0 nmSupplementary Table 2, internal p. 25 / PDF p. 26
Literature-reported0.133Post-formulation characterization · Representative cKK-E12 LNP: 0.155Supplementary Table 2, internal p. 25 / PDF p. 26
Literature-reportedapproximately 7.5Post-formulation characterization · Approximately 6.5 is described as characteristic of the cited liver-tropic formulationsMain text p. 11; Supplementary Figure 21b
Literature-reportedapproximately four-fold higher6 h after a single 1 microgram IV FLuc-mRNA dose · Versus cKK-E12 LNP; reduced liver signal was also reportedMain text p. 9; Extended Data Figure 4c,d
Additional reported findings
AMG514-formulated NIK plus OVA generated approximately 15% OVA-tetramer-positive CD8 T cells after boosting, compared with approximately 6% for the cKK-E12 formulation.
C57BL/6J mice; total 3 micrograms RNA; days 0 and 14; n=5; route not stated for this experiment · Main Figure 6f-h and text p. 11AMG514 NIK plus OVA produced complete rejection in five of five mice, compared with three of five for cKK-E12 NIK plus OVA and one of five for AMG514 OVA alone. The authors state that the AMG514 advantage over cKK-E12 was not statistically significant.
Preclinical prophylactic vaccine and tumor-challenge study · Main Figure 6i,j and text p. 11The reported AMG514 corona was enriched in vitronectin, coagulation proteins and selected apolipoproteins. This association does not by itself prove a receptor-mediated targeting mechanism.
The main text refers to plasma, while the Supplementary Figure 21 caption refers to serum · Main text p. 11 and Supplementary Figure 21Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetGupta A, Das R, Reed K, et al. Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. Nature Biotechnology. Published online 13 May 2026. DOI: 10.1038/s41587-026-03115-2
Structure and analytical identity: Extended Data Figure 4a and Supplementary chemical-characterization section; formulation and preparation: Supplementary Table 1 and Methods; reporter delivery: Extended Data Figure 4; vaccination and tumor-challenge findings: Figure 6; protein corona and apparent pKa: main text and Supplementary Figure 21.
Structure and analytical identity: Extended Data Figure 4a and Supplementary chemical-characterization section; formulation and preparation: Supplementary Table 1 and Methods; reporter delivery: Extended Data Figure 4; vaccination and tumor-challenge findings: Figure 6; protein corona and apparent pKa: main text and Supplementary Figure 21.